Aagami

LifeSciences Catalysts

November 2026

23+
Years

130+
Clients

30+
Countries

235+
Projects



Global Advisory
Strategic Consulting

→ **Realizing Possibilities, Together** ←

2020 Calamos Court, Suite 200, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com

ABOUT US

Aagami, Inc.

Pharma

Medical Devices

Global Advisory

SPECIALIZING IN

Strategic Consulting

Biotech

Consumer Healthcare

130+ Clients

235+ Projects

30+ Countries

OUR SERVICES

Your Needs We Serve

Our services to achieving aspirations



M&A / Divestiture

Support in M&A and Divestment of **Assets, Techs, IP, Companies** etc.



Funding / Investment

Advisory and BD support for Funding and Venture Capital needs



Partnership / Co-development

Various types of development partnering **support**



Licensing / Commercialization

Support all stages of licensing **(Product/IP/Tech)** from Pre-Clinical to on the Market

WHY AAGAMI

Aagami brings,

Deep Experience of overcoming business and socio-cultural differences among various countries/regions

Our partners have lived and worked in **US, India, Japan, Germany, China, Canada, Spain, Brazil, Colombia**, etc.

Extensive 'C' level network nurtured for **23+ years**

Global Deal making experience of **250+ years** of all Partners combined

Market Intelligence and IP Research using **new age tools**

Augmenting your team to **save time, effort & cost**

Note: We do not replace your invaluable team, just be an extension

OUR CLIENTS

Sample list of Clients

Delivered **235+ projects** for **130+ clients** worldwide

USA

NanoViricides Incorporated

RTx Resuscitation Therapeutics Inc

AMYTRX Therapeutics

LIVIONEX®

promaxo

CMX Twenty

United Research Laboratories

Impel NeuroPharma

OncBioMune Pharmaceuticals Inc

MICOY Therapeutics

neuro42

PLUS Therapeutics

International

FirebrickPharma — Australia

KiOmed Pharma — Belgium

普莱医药 ProteLight Pharma — China

NFL Biosciences — France

pieris Pharmaceuticals — Germany

ipca A dose of life — India

Opsona Therapeutics — Ireland

Elcam Medical Where everything connects — Israel

MEDRx — Japan

Temple Therapeutics — Netherlands

honey lab® — New Zealand

UTRI — Norway

Hovione — Portugal

THYROSCOPE — S. Korea

GETINGE — Sweden

GALEN Advancing Human Health — UK

TRACK RECORD

Samples of diverse successes

(More Details in Case Studies). In most cases, Deal Size/ Partner Name is CONFIDENTIAL

Dietary Supplements

Equity Investment. AU $17M initial deal done. Total deal value of AU $50M+ on Acquisition

CONFIDENTIAL

Portable MRI System

Numerous Investments incl. Corporate Venture. *Secured partnership with a VA hospital*

CONFIDENTIAL

Biosimilar Licensing for Japan

CONFIDENTIAL

Finding customers for Peptides API

Partnered with 8 Companies

CONFIDENTIAL

Technology Licensing of Dermal Delivery Platform

4 Deals signed with 3 companies for 18 geographies

Co-Development Partnership for Novel Protein Therapeutic Platform

2 Deals Done

IN THEIR WORDS

Client Testimonials

> Virtues include Aagami's attentiveness, network, and integrity. Excellent and will recommend to all

— Founder and CEO of a California Biopharma



> Aagami is the bridge that crosses many gaps. Importantly it does so openly and honestly.

— Founder and CEO of a publicly Listed Australian Technology Development Company



> Other Consultants we worked with in the US and Canada do not even stand in Aagami's shadow

— CEO of a Specialty Chemicals company of Canada



> Pleased by Aagami's professional and gracious work. Delighted to recommend to others

— CEO of Oregon Biotech



OUR FOCUS

Our expertise & experience is of Strategic Deals

We are Agnostic about drug, device or therapy type

- **Aagami** is drug, device or therapy agnostic, we work on the business side with decision makers of companies of all sizes in Biologics, Pharma and Medtech from across the globe.

- We have served **130+ clients** from over **30 countries** and are well positioned to execute the deal for you.



OUR TEAM


Aagami – Core Team

Partners cumulative experience 250+ Years



Dinesh Jain, MBA
Founder
Working since 1984 · Managed several companies as CEO, VP, etc · Lived and worked in US, India, Japan and Spain.

USA



Michael Rosen, MBA
Partner
Since 1974, Managed 3 MNC Pharma, Agritech · US, Europe, Latin America, Japan & Israel

USA



Dr. Aman Ahuja, M.D., F.P.M., F.R.C.A.
Medical, Clinical Advisor
Pain Specialist and Anaesthetist uses multidisciplinary approach · Practicing since 1998

Australia



Dr. Shridhar Andurkar, Ph D
Scientific Advisor
Chair and Prof. of Pharmaceutical sciences, Midwestern Univ., Chicago College of Pharmacy · Working since 1991

USA



Dr. John Z. Zhu, Ph D
Partner
25+ yrs in Biopharma BD & Clinical Development · Multi-lingual, Multi-cultural · Also Co-founder of Mayewell Capital

USA & China



Christopher Aleong
Partner
25+ years in Pharma & Biotech · Bayer, Abbott, AbbVie, Sanofi · Lived & worked in US, China, Canada, Singapore & Taiwan

Canada



Dr. Carlos Velez, Ph D, MBA
Partner
Working since 1998 · CMTx, Lacerta, Connexin, Panion, Ventac, Penwest, Frankel

USA



Godwyn Francis
Vice-President
60+ BioPharma clients · Ex-Accenture, Prudential plc, TATA, pManifold · Working since 2000 · Lived and worked in India and UAE

India



Akshay Bavaria
Associate Director
25+ BioPharma clients · Business Development and Consulting since 2013

India

Affiliate Partners based in Europe and Asia too

HOW WE WORK

Aagami's Proven Methodology & Work Plan

Setup

Up to 1 month

- Capture important details about your assets/technologies.
- Work with you to Finalize '**Elevator Pitch (EP)/Teaser**' customized to specific business culture
- Identify relevant companies and decision makers from our relationships, and resources nurtured over 23+ years
- Then Shortlist further based on mutually agreed Criteria with your review and approval

Prospect

3 to 5 months

- Send Elevator Pitch/Teaser by **individual emails** to each of shortlisted Companies
- Follow-up with phone calls and emails, if necessary
- Coordinate CDAs with interested Companies and You
- Facilitate further information exchange and due diligence
- Organize conference calls for clarifications

Finalize

1 to 12+ months

- Organize and manage meetings for deal finalization
- **Advise on structuring the deal (Very important)**
- ***Support in negotiations (Most critical)***
- Complete Agreement

All these steps require 60 to 80 hours of effort every month depending upon scope

HOW WE ENGAGE

Consulting Model

Monthly Commitment Fee + Success Fee

Dedicated Teamwork

- A team of **Managing Partner, Vice President, Director and BD Manager**
- Works with focus on your success for our bonus

Small Monthly 'Commitment' Fee

for at least 6 months

- This binds ('**brings skin in the game**' of) both parties
- After 6 months you may continue based on experience

Success bonus

A small % of deal value

- Reducing Percentages Formula from 7% to 3% is an option
- **Our profits come from Success Bonus ONLY**

We also work on a simple hourly basis with no minimums

CLIENT OPPORTUNITIES

Few client opportunities we are currently representing 1 of 4

For Licensing/Partnering: Market Stage Assets

1. **Dental gel (Marketed in the US & approved in EU)** for Prevention & Treatment **of Periodontitis, Gingivitis, & Caries.** Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available. **US sales $40.2M in 2025.**

2. **Licensing Available:** FDA-Cleared Portable MRI & AI Guided Robotics Surgery Platform for Prostrate Cancer. Applicable for other indications too. **290+** systems sold and **$195M** in cumulative orders to date.

3. **Seeking Partner / Distribution in India: CE-marked single-injection bioresorbable implant (KioMedine vs One)** for Knee Osteoarthritis (OA). Patented non-animal carboxymethyl-chitosan with unique ROS-scavenging action. One Injection. Delivers 9–12 months of pain relief; proven efficacy in HA/steroid-refractory patients. Marketed across 25+ countries. Rights remain available for India, US, Japan and few other regions.

4. **High ROI Partnering Opportunity** in another U.S. (California) based medtech revolutionizing medical imaging, diagnosis and robotic surgery for **Brain and Head** (US FDA cleared). Focused on Strokes and TBI. Secured $24M in sales contracts for 2025 and 2026.

5. **First-in-class, broad-spectrum antimicrobial peptide** (Peceleganan / PL-5) targeting bacterial & fungal cell membranes with low resistance potential. **Market-approved in China for burn wound infections** (Phase 3b complete) and Phase 2-ongoing in the US for Diabetic Foot Infections (DFI).

CLIENT OPPORTUNITIES

Few client opportunities we are currently representing 2 of 4

For Licensing/Partnering/Co-development: [In-Development Stage]

1. **Phase 3 ready** (Green light by FDA) **Erythropoietin (EPO)** asset for Resuscitation from **Sudden Cardiac Arrest** (A groundbreaking approach).
   Seeking strategic partner/investment, and EPO supplier also.

2. **Phase 2 Broad-Spectrum Revolutionary Antiviral (PRV Eligible).** Includes the Coronavirus family, including SARS-CoV-2 (COVID, Long COVID), RSV, Influenza A (including H5N1 "Bird Flu"), as well as Smallpox/MPOX, Measles and Ebola.

3. **Phase 3-Ready Immunotherapy For Smoking Cessation.** 2 Injection dosing regimen with no side effect.

4. **FDA approved Phase 3 initiation.** Small molecule eye drop to treat Cataract **(First in class). Brings paradigm shift in OPTH.** Conducting a Phase 2B to reduce risk. Partnering on hold until then (Q2, 2027).

5. **Seeking Licensing/Partnering: Biobetters** Clinical-stage portfolio of 2nd & 3rd-gen therapeutic enzymes (Phase 1) engineered to address known immunogenicity and short half-life limitations. Targets include PKU, ALL/LBL, and ASS1-deficient solid tumors, featuring extended dosing intervals and strong safety profiles.
   Estimated market approval ~2029-2030

6. **Seeking Licensing/Partnering:** Phase 3-Ready Drug safety-optimized to treat Atrial Fibrillation (AF); eliminates 3-day hospital onboarding for outpatient prescribing (dofetilide + mexiletine). FDA protocol reviewed, addressing 33M+ global market **with >$1B peak sales potential**.

7. **Available for Licensing/Co-development:** Biosimilars such as **Rituximab, Denosumab & Infliximab** with ~2028-29 market launch timeline. **Adalimumab** (2029-2030). **Trastuzumab + Pertuzumab** (Phesgo Biosimilar) & **Trastuzumab ADC** (Enhertu Biosimilar), **Dupilumab** (Dupixent Biosimilar) with 2031-32 market launch, **Pembrolizumab** 2029 (Keytruda Biosimilar).

Few client opportunities we are currently representing 3 of 4

Investment Opportunities

1. **High ROI Opportunity to Invest** in U.S. based MedTech revolutionizing medical imaging with the world's first portable, single-sided MRI platform for **Prostrate Cancer (On the market)**. **Exit** via an IPO, strategic M&A, or private equity buyout. Currently raising last round - Series C targeting up to $70M.

2. **Seeking Investment ($30–$40 Million Series A):** High-ROI opportunity in Phase 3-ready cardiovascular drug targeting Atrial Fibrillation with **>$1B peak annual sales potential**. Funds will be used for Phase 3 clinical trials, CMC manufacturing readiness, and FDA NDA filing. Exit via Strategic M&A or IPO.

3. **Seeking Investment (US$ ~3.76 Million raised in 2026): Join Investors such as BIRAC** in uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.

4. **High ROI Opportunity to Invest** in another U.S. based medtech revolutionizing medical imaging for **Brain and Head** (US FDA cleared). Exit via an IPO, strategic M&A, or private equity buyout. Current Focus is on Strokes and TBI. Secured $24M in sales contracts for 2025 and 2026. Currently raising up to $40M Series B, of which $20M is already closed.

Few client opportunities we are currently representing

For Acquisition

1. Available at a very reasonable price Mountain View Pharma (MVP) including its **PharmaPEG® technology for Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.**

2. **A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia).** (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for **US$400 million**.

3. **[URGENT]** Lucrative Opportunity to acquire IP Portfolio **(bankruptcy disposition)** of clinical stage **First-in-Class Non-Opioid Analgesic**. Bid under evaluation by Bankruptcy Trustee.

CASE STUDY

Biosimilar Licensing for Japan

Client: Biologics focused subsidiary of a Global Pharma

Client Need


- Client was struggling with Out-Licensing of their Denosumab Biosimilar for Japan and sought Aagami help.

Solution Approach

- Aagami used global expertise and network including in Japan, where CEO has lived and worked for 8 years, built 3 companies and speaks the language fluently.
- Aagami identified 30+ companies in Japan, including the companies already in Biosimilars business.
- Represented client in numerous partnering conferences and got them 20+ meetings.
- Japan is a tough region for Biosimilar licensing. So Aagami used its deep experience of overcoming business and socio-cultural differences and ultimately got serious partners from Japan.
- Facilitated entire evaluation and deal finalizing process.

Results

- ***Agreement signed for Denosumab for Japan, in Nov 2025.***
- Aagami also brought them serious interest from companies for Canada, South Korea and Europe region, not only for Denosumab, but also Romiplostim Biosimilar.



DENOSUMAB

ENZENE

Japan Licensee
Name Confidential

**Data has been sanitized and meant for illustrative purposes only*

CASE STUDY

US Licensing of Patented 505(b)(2) Lidocaine patch

Client: Japan based publicly listed Biopharma technology development company

Client Need

- They wanted to do US out-licensing of their patented Lidocaine patch which was in late stage


Solution Approach

- Aagami shortlisted and took them to 50+ companies which operate in the US.
- With focused efforts 10 companies had post CDA level scientific and technical data room due diligence.
- Generated interest from other regions too.
- 4 companies moved to term sheet level discussions.
- This is an ongoing project, and the final deal is expected to be signed in 2026.

Results

- Client signed the binding term sheet on May 15, 2026. The definitive agreement expected be signed by end of Nov 2026.
- The client has been very satisfied and has given multiple projects to Aagami, the latest in 2026.





Client and Its Partner Name Confidential

**Data has been sanitized and meant for illustrative purposes only*

CASE STUDY

Equity Investments for Portable MRI System

Client: California company bringing MRI with AI and robotic-guidance system for in-office use

Client Need

- Raising investments for their Series A round, followed by Series B(1-5). They have developed a unique MRI System that combines AI and Robotics.

Solution Approach

- Aagami identified right investors, and took them to 50+ investors/firms.
- With focused efforts several companies had post CDA level discussions.
- Aagami kept facilitating and persevering, which led to successes.
- The client gave further assignments and Aagami also supported their series B.
- Aagami have been successful in facilitating several investments. More discussions are ongoing.

Results

- Aagami have been successful in supporting them secure multi-million investments from Corporate Ventures and HNWI.
- Also secured partnership with a VA hospital.
- Client gave repeat assignments and recommended Aagami to other companies also.



**Data has been sanitized and meant for illustrative purposes only*

CASE STUDY

Equity Investment & Possible Full Acquisition

Client: Australia based company with novel technologies to express and harvest nutraceuticals in Algae

Client Need

- Investments/M&A for commercial development of its Technologies and assets.

Solution Approach

- Aagami identified right investors / partners and took them to 20+ companies.
- With focused efforts 3 companies had post CDA level scientific and technical discussions.
- Aagami kept facilitating and persevering, 1 large company moved to term sheet level discussions.
- Aagami travelled with client CEO to meet Chairman of Strategic company to finalise the deal
- Supported client through structuring of the deal and negotiations. Continued to support after the term sheet and till definitive agreement was completed.

Results

- Large Pharma, acquired 12.5% stake in WRS with a provision to acquire over 50% on agreed milestone completion.
- Based on the progress, the agreement has been signed for **100% acquisition**.



WRS Bioproducts
Renewable Growth – Naturally Healthy

Name of client partner is CONFIDENTIAL

**Data has been sanitized and meant for illustrative purposes only*

CASE STUDY

Out-licensing of Transdermal Drug Delivery Technology

Client: TPM® Technology and Products Company from Australia

Client Need

- To Out-License TPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and larger region.

Solution Approach

- Aagami scanned numerous companies and got 10 relevant companies interested.
- Discussion with 8 companies progressed.
- Took client to India 3 times for term sheet level meetings and deal signing.
- Facilitated entire evaluation and deal structuring process
- Aagami made sure testing and other protocols were honoured before deal was made.
- During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.

Results

4 Deals done with 3 global companies

– The first deal was for diclofenac topical gel formulation with TPM. **The Indian partner not only launched their own product but also out licensed to a major western pharma. Expanded to 16 geographies worldwide.**

– The second alliance was for use in Skin Whitening and under eye cream.

– Third deal – The prospect using TPM increased bio availability as well as stability of a specific antibiotic. **Then sold off that division for $1.6B**

Phosphagenics

THEMIS MEDICARE

INTAS

Strides ARCOLAB LIMITED

NOVARTIS

Mylan

*Data has been sanitized and meant for illustrative purposes only

CASE STUDY

Partnerships for Novel Class of Protein Drugs

Client: German Biotech company

Client Need


- The client wanted collaborative partners to develop novel drugs in **Oncology** and **Ophthalmology** using their new class of proteins - Anticalins®.

Solution Approach

- Aagami identified right partners, and took them to 7 interested companies
- With focused efforts 3 companies moved to term sheet level discussions. 2 companies remained for final negotiations.
- Aagami persevered knowing Indian ways of working; even when client was ready to give up as per Western ways.
- Finally, co-development partnership happened in few months with a company in Oncology and with another for ophthalmic.
- **Identifying right companies, advice on deal structure, perseverance & commitment were the key success factors.**

Results

- Client signed co-development deals with 2 companies.
- Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India.
- **The deals helped Pieris in their NASDAQ (PIRS) listing.**



pieris

Zydus Cadila

Stelis Biopharma

**Data has been sanitized and meant for illustrative purposes only*

Aagami
LifeSciences Catalysts

Dinesh Jain
Founder
dinesh@aagami.com
+1-630-853-3520

Godwyn Francis
Vice-President
godwyn@aagami.com
+1-630-364-1837

Aagami, Inc.
2020 Calamos Court, Suite 200
Naperville, IL 60653, USA
+1-630-364-1837
www.aagami.com





